Clinica Los Remedios is categorized under Blood Related Health Services in Los Angeles, CA and active since 2011.
Clinica Los Remedios was established in 2011, and today employs 1 to 4, earning $1.000.000 to $2.499.999 per year. This is a Blood Related Health Services business, which does work in the B2C market, and is classified as a Blood Related Health Services, under code number 6214930 by the NAICS.
If you are seeking more information, feel free to contact Georgina Makabali, Owner at the company’s single location by writing to 2400 West 7th St # 114, Los Angeles, California CA 90057 or by phoning (213) 389-2556. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
Business Name: | Clinica Los Remedios |
Contact Person: | Georgina Makabali, Owner |
Address: | 2400 West 7th St # 114, Los Angeles, California 90057 |
Phone Number: | (213) 389-2556 |
Annual Revenue (USD): | $1.000.000 to $2.499.999 |
Founded: | 2011 |
Location Type: | Single Location |
Employee Number: | 1 to 4 |
Business Type: | B2C (Business to Consumer) |
Business Category: | Blood Related Health Services |
SIC Code: | 8099 |
NAICS Code: | 6214930 |
Share This Business: |
Clinica Los Remedios was started in 2011 to provide professional Blood Related Health Services under the SIC code 8099 and NAICS code 6214930. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $1.000.000 to $2.499.999 per annum.
Feel free to contact Georgina Makabali, Owner for inquiries that concern Clinica Los Remedios by calling the company number (213) 389-2556, as your correspondence is most welcome. Additionally, the physical location of the single location of Clinica Los Remedios can be found at the coordinates 34.057799,-118.27991 as well as the street address 2400 West 7th St # 114 in Los Angeles, California 90057.
For its online presence, you may visit Clinica Los Remedios’s website at and engage with its social media outlets through on Twitter and on Facebook.